Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 7,631 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 42
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 37 more

Conditions: Acne
Interventions: Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, placebo gel; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,001 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 14 more

Conditions: Breast Cancer
Interventions: Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 386
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more

Conditions: Chronic Hepatitis C
Interventions: SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 38
States / cities: Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more

Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging; Procedure · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 178
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more

Conditions: Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Loma Linda, California • Los Angeles, California + 29 more

Conditions: Binge Eating Disorder
Interventions: Dasotraline; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 57
States / cities: Phoenix, Arizona • Beverly Hills, California • Encino, California + 52 more

Conditions: Paroxysmal Supraventricular Tachycardia
Interventions: Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System; Drug · Device
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more

Conditions: Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
Interventions: BIO101, Placebo; Drug
Lead sponsor: Biophytis; Industry
Eligibility: 65 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 19
States / cities: Banning, California • Garden Grove, California • San Diego, California + 15 more

Conditions: Ankle Fracture
Interventions: Repair Deltoid Tendon, Ankle Fracture Without Deltoid Tendon Repair; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Arrhythmia, Bradycardia
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 2,927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 110
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 107 more

Conditions: Visual Acuity
Interventions: JJVC Investigational Multifocal Toric Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 8
States / cities: Jacksonville, Florida • Maitland, Florida • Pittsburg, Kansas + 4 more

Conditions: Cardiovascular Disease
Interventions: Olpasiran, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Bridgeport, Connecticut • Jacksonville, Florida • Overland Park, Kansas + 3 more

Conditions: Brain and Central Nervous System Tumors
Interventions: BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy, CCNU, BCNU 150mg/m2, BCNU 200mg/m2, TMZ 150mg/m2 six 6-week cycles, TMZ 150mg/m2 six 8-week cycles; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2018
U.S. locations: 92
States / cities: Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more

Conditions: Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 219
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 28
States / cities: Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 23 more

Conditions: IgA Nephropathy (IgAN)
Interventions: Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Elafibranor, Placebo; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 153
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole, placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 53
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more

Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions: Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy; Biological · Drug · Procedure + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 342
States / cities: Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more

Conditions: Systemic Lupus Erythematosus
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 132
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more

Conditions: Brain and Central Nervous System Tumors
Interventions: carmustine, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 218
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more

Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Interventions: Endogenex Treatment, Sham Procedure; Device
Lead sponsor: Endogenex, Inc.; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Gardena, California • Los Angeles, California + 24 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Study of Oral Treatments for Hepatitis C

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Dasotraline Binge Eating Disorder Extension Study

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

Is Deltoid Ligament Repair for Ankle Fracture Necessary?

MEDTRONIC ADAPTA, VERSA AND SENSIA nEw3 POST APPROVAL STUDY

Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Aripiprazole in Children and Adolescents With Bipolar I Disorder

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events